Regardless of PD-L1 status, bispecific immune checkpoint inhibitors improve survival in patients with gastric cancer.

Published Date: 10 Apr 2024

Patients with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal cancer showed improved progression-free survival and overall survival when treated with chemotherapy and the PD-1/CTLA-4 bispecific antibody cadonilimab.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Breast Cancer Patients Living Longer Post-Medicaid Expansion

2.

Error on the MGUS-Autoimmune Disease Association.

3.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

4.

The majority of cancer medications that receive expedited approval end up failing confirmatory trials.

5.

Unified Neuro/Psych Residency Program: New Proposal.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot